Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing

BlueRock Therapeutics is focused on breakthrough treatments based on latest stem cell technology in combination with superior cell differentiation protocols / BlueRock Therapeutics’ vision is to cure diseases with significant cell loss and diminished self-repair potential with an initial focus on cardiovascular, neurological and other conditions
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news